Navigation Links
Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
Date:2/19/2009

all pending litigation brought by certain former dissenting shareholders of Transkaryotic Therapies, Inc. ("TKT"). As a result of this settlement, Shire paid the former dissenting shareholders the same price of $37 per share originally offered to all TKT shareholders at the time of the 2005 merger, plus interest. The settlement represents a total payment of $568 million, comprising consideration at $37 per share of $420 million and an interest cost of $148 million. - During the fourth quarter we increased our voting interest in Jerini to over 98%. Achieving a holding of more than 95% enabled Shire To initiate on December 16, 2008 the legal process to compulsorily acquire the remaining shares in Jerini.

2009 OUTLOOK

Our business model remains differentiated and attractive. It is based on addressing high unmet medical needs within specialist fields, developing drugs that treat symptomatic and/or rare diseases with strong intellectual property and/or regulatory protection. We will continue to replenish our portfolio of products via in-licensing, acquisitions and our own development efforts, as well as expanding our geographical reach and lead in the markets we serve.

We believe that our new product portfolio will continue to deliver strong, high margin growth throughout 2009 and 2010 and provide the platform for future revenue and earnings growth. We have assumed a significant decline in ADDERALL XR sales in 2009 but we have recognized that there are a number of variables that will influence the outcome. As a result, while continuing to invest in the future drivers of our business, we will flexibly manage our discretionary cost base to minimize any variation in expected earnings as the year develops.

We are reiterating our previously announced guidance framework for Non GAAP diluted earnings per ADS for 2009, which rem
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
2. Shire plc: Change to Directors Details
3. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
4. Shires New Product Portfolio Delivers Strong Quarterly Performance
5. Change of Name to Shire plc
6. Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
7. Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
8. Shire Re-Launches ADHDSupport.com, a Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)
9. Shire Ltd.: Robin Buchanan to Step Down as Non-Executive Director on Completion of Term of Office
10. Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008
11. Graham Hetherington Appointed Chief Financial Officer and Board Director at Shire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... BRUSSELS, December 14 , ... Lifestyles of,Women With Rheumatoid Arthritis in Seven Major Industrialized Countries ... living with rheumatoid arthritis say their disease, ... - Women living with rheumatoid arthritis find shopping ... writing cards and wrapping presents most, ...
(Date:12/11/2009)... (Nasdaq: DNDN ) announced today that the ... exercised in full their option to purchase an ... public offering price of $24.75 per share. ... of the offering to an aggregate of 17,250,000 ... receive net proceeds from the offering of approximately ...
(Date:12/11/2009)... a new explanation for differences in the severity of mental ... gene, the more serious the handicap. The genetic defect is ... is the amount of copies of the GDI1 gene that ... American Journal of Human Genetics , and are the result ... VIB, a life sciences research institute in Flanders, Belgium at ...
(Date:12/11/2009)... Dec. 11 Ambit Biosciences Corporation announced today ... M. D. Anderson Cancer Center of the first patient ... E fficacy) Phase 2 pivotal trial ... (AML). AC220 is a novel, orally available, potent ... as a FMS-like tyrosine kinase-3 (FLT3) inhibitor. The ...
Breaking Biology Technology:Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Amount of gene surplus determines severity of mental retardation in males 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5
... allowing for the rapid ... molecules using a single reaction, ST. LOUIS, Oct. ... it has signed an exclusive licensing,agreement with the University ... of powerful new boronic acid,surrogates for use in Suzuki-Miyaura ...
... focus on new patient data supporting the Ross heart, reconstruction ... ... Ross procedure, ATLANTA, Oct. 7 CryoLife, Inc. (NYSE: ... cardiovascular surgeons from around the globe will participate in the,Ross Summit ...
... U.S. National Institutes of Health, The Infectious Disease ... Launch and Board of Advisors, SEATTLE, Oct. ... announced its first acquisition of compounds for further,development ... Summit plc (LSE: SUMM) of Oxfordshire, UK, and ...
Other Biology Technology:Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement 2Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement 3CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure 2CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure 3CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure 4Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 2Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 3Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 4Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 5
(Date:12/11/2009)... . , Montreal, December 11, 2009 ... prevents cancer. In the December 11 edition of the ... Universit de Montral and the Universit de Sherbrooke explain ... cancer-causing activity of cytokines, hormones that are culprits in ... and people exposed to asbestos. , "Excessive cytokine ...
(Date:12/11/2009)... editor of the 4th edition of Springer,s classic reference ... given the Victor A. McKusick Leadership Award. The prize, ... of human genetics, was presented to him at the ... Genetics on 24 October 2009 in Honolulu, Hawaii. , ... at the University of Washington in Seattle. One of ...
(Date:12/11/2009)... have traditionally been limited by the seasons, ... can be short. Thanks to researchers and ... introduced that offer growers the ability to ... bonuses for both producers and consumers. Fresh ... called "primocane-fruiting", which bear fruit on current-season ...
Breaking Biology News(10 mins):Scientists identify natural anti-cancer defenses 2New management methods extend blackberry season 2Keystone Mercy Health Plan Initiative Brings Cancer Screenings to Underserved Women in Their Communities 59860 1Keystone Mercy Health Plan Initiative Brings Cancer Screenings to Underserved Women in Their Communities 59860 2Keystone Mercy Health Plan Initiative Brings Cancer Screenings to Underserved Women in Their Communities 59860 3Keystone Mercy Health Plan Initiative Brings Cancer Screenings to Underserved Women in Their Communities 59860 4Karmanos Cancer Institute Immunology Researcher Obtains Nearly 241 Million National Institutes of Health Grant 59855 1Karmanos Cancer Institute Immunology Researcher Obtains Nearly 241 Million National Institutes of Health Grant 59855 2Karmanos Cancer Institute Immunology Researcher Obtains Nearly 241 Million National Institutes of Health Grant 59855 3Pulmo BioTech Inc Announces Letter of Intent Regarding Proposed License of its Pulmonary Vascular Diagnostic Product Candidate PulmoBind 28TM 29 5618 1Pulmo BioTech Inc Announces Letter of Intent Regarding Proposed License of its Pulmonary Vascular Diagnostic Product Candidate PulmoBind 28TM 29 5618 2Pulmo BioTech Inc Announces Letter of Intent Regarding Proposed License of its Pulmonary Vascular Diagnostic Product Candidate PulmoBind 28TM 29 5618 3Pulmo BioTech Inc Announces Letter of Intent Regarding Proposed License of its Pulmonary Vascular Diagnostic Product Candidate PulmoBind 28TM 29 5618 4
... Male fruit flies missing a gene for one particular odor ... Duke University Medical Center have discovered. , Because they ... will indiscriminately attempt to have sex with other males, and ... are pheromones wafting from mated females and male flies. ...
... Recognizing his strong support for agriculture and the conservation of ... the 2008 Excellence in Soil Stewardship Award presented by the ... fifth generation Coloradan, Senator Salazar grew up on a ranch ... and ranched the land since homesteading. The Senator serves on ...
... scientists has identified a protein able to stimulate the production ... and the elimination of infectious agents. The discovery by researchers ... at the Universit de Montral in Canada and the University ... of the journal Immunity could help to ...
Other Biology News:1 missing gene leads to fruitless mating rituals 2Identification of protein able to stimulate production of T-cells 2
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Purified anti-PI3K p110 delta...
Peptide-affinity Purified Polyclonal Antibody to Histamine H2 Receptor...
Mouse Wnt-9b Biotinylated Affinity Purified PAb ENTREZ GeneID: 22412...
Biology Products: